Insider Buying: VYNE Therapeutics Inc. (NASDAQ:VYNE) Director Purchases $43,800.00 in Stock

VYNE Therapeutics Inc. (NASDAQ:VYNE) Director Patrick G. Lepore bought 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were acquired at an average cost of $2.92 per share, with a total value of $43,800.00. Following the transaction, the director now owns 51,472 shares in the company, valued at approximately $150,298.24. This represents a 41.13 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

VYNE Therapeutics Stock Up 4.7 %

VYNE opened at $2.70 on Friday. The firm has a market capitalization of $39.83 million, a P/E ratio of -3.14 and a beta of 1.30. The firm’s 50 day moving average is $2.95 and its 200-day moving average is $2.36. VYNE Therapeutics Inc. has a 52-week low of $1.57 and a 52-week high of $4.30.

Analysts Set New Price Targets

VYNE has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $5.75 target price on shares of VYNE Therapeutics in a research report on Tuesday, January 14th. BTIG Research started coverage on shares of VYNE Therapeutics in a research note on Monday, November 18th. They set a “buy” rating and a $8.00 price objective on the stock.

Institutional Trading of VYNE Therapeutics

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP purchased a new position in VYNE Therapeutics Inc. (NASDAQ:VYNE) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics comprises about 0.0% of Lynx1 Capital Management LP’s holdings, making the stock its 17th largest holding. Lynx1 Capital Management LP owned about 0.11% of VYNE Therapeutics at the end of the most recent reporting period. 83.78% of the stock is currently owned by institutional investors.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.